Analysts have set 12-month price targets for Alkermes, revealing an average target of $42.0, a high estimate of $52.00, and a ...
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback